- Home
- SPRO vs BLUE Comparison
SPRO vs BLUE Comparison
Compare SPRO & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- BLUE
- Stock Information
- Founded
- SPRO 2013
- BLUE 1992
- Country
- SPRO United States
- BLUE United States
- Employees
- SPRO N/A
- BLUE N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPRO Health Care
- BLUE Health Care
- Exchange
- SPRO Nasdaq
- BLUE Nasdaq
- Market Cap
- SPRO 40.5M
- BLUE 36.9M
- IPO Year
- SPRO 2017
- BLUE 2013
- Fundamental
- Price
- SPRO $0.62
- BLUE $3.50
- Analyst Decision
- SPRO Buy
- BLUE Hold
- Analyst Count
- SPRO 4
- BLUE 7
- Target Price
- SPRO $5.00
- BLUE $44.60
- AVG Volume (30 Days)
- SPRO 113.5K
- BLUE 160.2K
- Earning Date
- SPRO 05-13-2025
- BLUE 05-20-2025
- Dividend Yield
- SPRO N/A
- BLUE N/A
- EPS Growth
- SPRO N/A
- BLUE N/A
- EPS
- SPRO N/A
- BLUE N/A
- Revenue
- SPRO $47,977,000.00
- BLUE $83,807,000.00
- Revenue This Year
- SPRO N/A
- BLUE $218.58
- Revenue Next Year
- SPRO N/A
- BLUE N/A
- P/E Ratio
- SPRO N/A
- BLUE N/A
- Revenue Growth
- SPRO N/A
- BLUE 184.12
- 52 Week Low
- SPRO $0.51
- BLUE $3.56
- 52 Week High
- SPRO $1.72
- BLUE $28.60
- Technical
- Relative Strength Index (RSI)
- SPRO 41.34
- BLUE 32.56
- Support Level
- SPRO $0.64
- BLUE $3.62
- Resistance Level
- SPRO $0.75
- BLUE $4.45
- Average True Range (ATR)
- SPRO 0.05
- BLUE 0.25
- MACD
- SPRO -0.01
- BLUE -0.05
- Stochastic Oscillator
- SPRO 21.63
- BLUE 1.83
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.